Publications by authors named "Nicholas Bellos"

Claim this Profile
C
Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
Andrew M Hill, Bonaventura Clotet, Margaret Johnson, Matthias Stoll, Nicholas Bellos

Pharmacoeconomics· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
Kathleen E Squires, Benjamin Young, Edwin DeJesus, Nicholas Bellos, Daniel Murphy

HIV Clin Trials· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enfuvirtide does not require dose adjustment in patients with chronic kidney failure: results of a pharmacokinetic study of enfuvirtide in HIV-1-infected patients with impaired kidney function.
Pablo Tebas, Nicholas Bellos, Christopher Lucasti, Gary Richmond, Eliot Godofsky

J Acquir Immune Defic Syndr· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Bonaventura Clotet, Nicholas Bellos, Jean-Michel Molina, David Cooper, Jean-Christophe Goffard

Lancet· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation.
Joseph J Eron, John A Bartlett, Jorge L Santana, Nicholas C Bellos, Judy Johnson

J Acquir Immune Defic Syndr· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis